Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer

Experimental and Therapeutic Medicine

Volumn 2, Issue 2, 2011, Pages 251-256

  Inokuchi, Mikito ^a   Murayama, Tadao ^a   Hayashi, Mikiko ^a   Takagi, Yoko ^a   Kato, Keiji ^a   Enjoji, Megumu ^a   Kojima, Kazuyuki ^a   Kumagai, Jiro ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Epidermal growth factor receptor; Gastric cancer; Mammalian target of rapamycin; Signal transducer and activator of transcription 3

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; TUMOR GROWTH;

EID: 79551626045     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.187     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Yonemura Y, Sugiyama K, Fushida S, Kamata T, Ohoyama S, Kimura H, Yamaguchi A and Miyazaki I: Tissue status of epidermal growth factor and its receptor as an indicator of poor prognosis in patients with gastric cancer. Anal Cell Pathol 3: 343-350, 1991.
3. Hirono Y, Tsugawa K, Fushida S, Ninomiya I, Yonemura Y, Miyazaki I, Endou Y, Tanaka M and Sasaki T: Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology 52: 182-188, 1995.
4. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18: 2201-2209, 2000.
5. García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P and García-Muñiz JL: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10: 234-241, 2003.
6. Hirashima Y, Yamada Y, Matsubara J, Takahari D, Okita N, Takashima A, Kato K, Hamaguchi T, Shirao K, Shimada Y, Taniguchi H and Shimoda t: impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer. Cancer Sci 100: 310-315, 2009.
7. Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W and Höcker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24: 228-240, 2006.
8. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T and Sugihara K: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14: 7843-7849, 2008.
9. Bang YJ, van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; for the ToGA Trial investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
10. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102: 1385-1392, 1998.
11. Coffer PJ and Kruijer W: EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem Biophys Res Commun 210: 74-81, 1995.
12. Schmelzle T and Hall MN: TOR, a central controller of cell growth. cell 103: 253-262, 2000.
13. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D and Sonenberg N: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94: 195-199, 2006.
14. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T and Sugihara K: Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 100: 782-788, 2009.
15. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 15: 2474-2488, 2000.
16. Levy DE and Lee CK: What does Stat3 do? J Clin Invest 109: 1143-1148, 2002.
17. Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K and Sekine I: Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol 30: 437-442, 2007.
18. Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI, Ko KH, Hwang SG, Park PW, Rim KS and Hong SP: STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 24: 646-651, 2009.
19. Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim do H, Kim KM and Park CK: Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 117: 598-606, 2009.
20. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 58: 833-838, 2005.
21. Park JK, Hong R, Kim KJ, Lee TB and Lim SC: Significance of p-STAT3 expression in human colorectal adenocarcinoma. Oncol Rep 20: 597-604, 2008.
22. Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J and Ahn MJ: Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer 116: 676-685, 2010.
23. Haura EB, Zheng Z, Song L, Cantor A and Bepler G: Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11: 8288-8294, 2005.
24. Sheen-chen SM, Huang CC, Tang RP, Chou FF and Eng HL: Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiol Biomarkers Prev 17: 2286-2290, 2008.
25. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L and Hung MC: Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat cell Biol 3: 802-808, 2001.
26. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY and Hung MC: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589, 2005.
27. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A and Martoni AA: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesopha-geal junction adenocarcinoma (DOCETUX study). Br J Cancer 101: 1261-1268, 2009.
28. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the Akt/ mammalian target of rapamycin/4E-Bp1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788, 2004.
29. Nam SY, Lee HS, Jung GA, Choi J, Cho SJ, Kim MK, Kim WH and Lee BL: Akt/pKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS 111: 1105-1113, 2003.
30. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG and Javle MM: Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13: 933-939, 2006.
31. Ma J, Meng Y, Kwiatkowski DJ, et al: Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 120: 103-114, 2010.